Added to YB: 2024-12-17
Pitch date: 2024-12-16
ABCL [bullish]
AbCellera Biologics Inc.
+24.83%
current return
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$1.6B
Pitch Price
$2.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.86
P/E
-9.77
EV/Sales
37.22
Sector
Life Sciences Tools and Services
Category
growth
AbCellera ($ABCL) a misunderstood gem: AbCellera explained and my full thesis
ABCL: Microfluidics leader in antibody discovery. COVID success proved concept. 95+ partnerships, 10 clinical molecules. $900M liquidity, 5-7yr runway. New GMP facility for in-house/partner trials. Risks: slow molecule advancement, patent litigation. Trading below cash value. Insider buying, gov't backing.
Read full article (18 min)